How Glucose–Fructose-Laden Drinks: Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, with metastatic disease accounting for the majority of fatalities. While genetics and lifestyle factors have long been recognized as contributors to CRC risk, emerging research highlights the significant role of diet not only in the development of cancer but also in its progression. Recent findings from the University of Texas MD Anderson Cancer Center suggest that sugar-sweetened beverages (SSBs), specifically those containing a mix of glucose and fructose, may actively fuel the spread of colorectal cancer.
The study, published in Nature Metabolism, identifies a critical molecular player, the SORD enzyme, which converts sorbitol to fructose. This enzyme appears to drive CRC metastasis, particularly to the liver, in preclinical models. The implications are significant: routine consumption of sugary drinks, including soda, energy drinks, and fruit juices, may directly influence cancer behavior, highlighting the importance of dietary interventions for CRC patients.
Senior author Jihye Yun, PhD, assistant professor of genetics at MD Anderson, emphasized that “daily diet matters not only for cancer risk but also for how the disease progresses once it has developed.” This research provides a crucial molecular explanation for the link between sugar intake and metastatic CRC, offering new avenues for therapy and lifestyle guidance.
The Role of Glucose and Fructose in CRC Progression
Sugar-Sweetened Beverages and Cancer Cell Motility
The MD Anderson study demonstrates that exposure to a combination of glucose and fructose, rather than either sugar alone, significantly enhances cancer cell motility and promotes metastasis in colorectal cancer. In preclinical models, this sugar mix was shown to drive liver metastasis by altering key metabolic pathways within cancer cells.
The mechanism involves the polyol pathway, where the NAD⁺/NADH ratio is elevated through activation of the reverse reaction of sorbitol dehydrogenase. This redox shift alleviates NAD⁺ limitations, accelerates glycolysis, and activates the mevalonate pathway, collectively fueling cancer cell migration and metastatic spread.
SORD Enzyme: A Key Driver of Metastasis
The study highlights SORD (sorbitol dehydrogenase) as a critical enzyme that converts sorbitol to fructose and boosts glucose metabolism. Activation of SORD by the glucose-fructose mix triggers downstream cholesterol pathways, which in turn promote CRC cell motility. Notably, inhibition or removal of SORD in the models significantly suppressed cancer cell migration even when the sugar mix was present, underscoring SORD’s role as a potential therapeutic target.
Implications for Diet and Nutrition in CRC
Dietary Habits Matter
These findings suggest that dietary intake, particularly the consumption of SSBs, can directly influence the behavior of colorectal cancer. Human epidemiological studies support this connection, showing that high SSB intake is correlated with increased CRC recurrence and mortality.
Previously, research from Yun’s lab indicated that SSBs promote tumor formation in early-stage CRC independent of obesity. Large-scale studies confirmed these results, linking sugar-sweetened beverages to a doubled risk of young-onset CRC.
Rethinking Nutritional Guidance for CRC Patients
Currently, cancer patients are sometimes advised to consume energy-dense drinks to maintain caloric intake during treatment. However, this research suggests caution for patients with advanced CRC, as glucose-fructose-laden drinks may inadvertently accelerate metastasis. Tailored dietary interventions focusing on reducing SSB consumption may therefore be a vital component of comprehensive CRC care.
Read about: Chemotherapy and Immunotherapy: Exploring Combined Treatment Approaches Explained by Dr. Pooja Babbar
Potential Therapeutic Approaches
Targeting the SORD Enzyme
The study identifies SORD as a promising therapeutic target. By inhibiting SORD, it may be possible to reduce CRC metastasis and block the metabolic pathways that drive cancer spread.
Repurposing Statins
Since the glucose-fructose mix activates downstream cholesterol synthesis via the mevalonate pathway, statins—which inhibit cholesterol synthesis—could serve as a potential adjunct treatment. Statins may be particularly beneficial for patients with high SORD expression and elevated sugar intake, providing a rationale for future clinical trials.
Future Directions
While these findings are currently limited to preclinical models, they open new avenues for research. Prospective studies in humans are needed to evaluate the interplay between SORD expression, dietary sugar consumption, and the efficacy of interventions such as statins. This research emphasizes the importance of personalized approaches to CRC management, integrating both diet and molecular targets.
Conclusion
This groundbreaking research underscores the critical role of diet, particularly glucose-fructose-laden drinks, in the progression of colorectal cancer. By identifying SORD as a key driver of metastasis, the study provides molecular insight into how sugar consumption can influence cancer spread.
Reducing the intake of sugary beverages may not only lower the risk of CRC progression but also improve outcomes for patients already diagnosed with the disease. Nutritional guidance should be reconsidered, especially for patients with advanced CRC who are at risk of metastasis.
Targeting SORD and exploring the use of statins offer promising therapeutic strategies, highlighting the need for further clinical investigation. Personalized approaches that combine lifestyle modifications and targeted treatments could significantly improve patient outcomes.
Ultimately, the study reinforces the importance of both preventive and therapeutic strategies in colorectal cancer care, demonstrating that simple dietary choices may have profound effects on disease progression and survival.
Also read: Indian Rupee Hits All-Time Low of 88.49 Against US Dollar Amid Weak Asian Cues
Frequently Asked Questions
1. How do glucose-fructose drinks promote colorectal cancer metastasis?
Research shows that a combination of glucose and fructose fuels cancer cell motility through metabolic pathways. The sugars elevate the NAD⁺/NADH ratio, accelerate glycolysis, and activate the mevalonate pathway, which enhances metastatic potential.
2. What is the role of the SORD enzyme in CRC progression?
SORD (sorbitol dehydrogenase) converts sorbitol to fructose and boosts glucose metabolism. Activation of SORD triggers downstream cholesterol pathways, driving CRC cell migration. Inhibition of SORD significantly reduces cancer cell motility and metastasis.
3. Should CRC patients avoid all sugary drinks?
While further clinical studies are needed, preclinical evidence suggests that glucose-fructose-laden drinks may accelerate metastasis. Limiting SSB intake, especially in advanced CRC, could be beneficial as part of a comprehensive dietary strategy.
4. Can statins help prevent CRC metastasis?
Statins inhibit cholesterol synthesis activated downstream of SORD in CRC cells. This pathway promotes metastasis, so repurposing statins could potentially reduce metastatic spread, especially in patients with high SORD expression and high sugar intake.
5. How does this research affect dietary guidance for cancer patients?
Patients are often advised to consume energy-dense drinks to maintain weight during treatment. However, for advanced CRC patients, high sugar intake may accelerate metastasis. This study suggests that dietary recommendations may need to be reconsidered to balance caloric needs with cancer progression risk.